About SenoRx
SenoRx is a company based in Irvine (United States) founded in 1998 was acquired by CR Bard in May 2010. SenoRx operates in a competitive market with competitors including Elucent Medical, Cianna Medical, OncoStem, Curasight and PreludeDx, among others.
- Headquarter Irvine, United States
- Stage Public
- SectorsHealthcare
- Website senorx.com
- Social LinkedIn
- Acquired by CR Bard (May 2010)
- Legal Name Senorx Llc
Investors in SenoRx
SenoRx has secured backing from 1 investor. Prominent investors backing the company include CR Bard.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Products for vascular, urology, oncology, and surgical specialties | 1907 | crbard.com | Murray, United States |
Investor details for SenoRx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of SenoRx
3 dated milestones of SenoRx across 12 years, from founding to its latest funding, stage changes and deals.
- Founded SenoRx is founded.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by CR Bard.
Competitors of SenoRx
SenoRx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Elucent Medical, Cianna Medical, OncoStem, Curasight and PreludeDx, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| elucentmedical.com | 2014 | Brookfield, United States | – | 11 | Develops smart surgical guidance systems with in-body spatial intelligence for accuracy. | |
| ciannamedical.com | 2007 | Aliso Viejo, United States | $49.5M | 2,709 | Breast brachytherapy devices and surgical guidance systems are developed. | |
| oncostem.com | 2011 | Bengaluru, India | $9M | 18 | Prognostic tests for cancer detection and recurrence risk are developed. | |
| curasight.com | 2013 | Copenhagen, Denmark | $11.54M | 9 | uPAR-based PET ligands for breast cancer imaging are developed. | |
| preludedx.com | 2009 | Laguna Hills, United States | $46.65M | 33 | Risk assessment tests for early-stage breast cancer are provided. | |
| mirtel.co.jp | 2012 | Hiroshima, Japan | $5.28M | – | Telomere tests for aging detection and cellular senescence are provided. | |
| pocmedicalsystems.com | 2013 | Livermore, United States | $22.1M | 58 | Develops rapid tools for breast cancer detection and disease screening worldwide. | |
| inbiomotion.com | 2010 | Barcelona, Spain | $4.91M | – | Biomarkers for predicting bone metastasis in cancer patients are developed. |
Detailed competitors of SenoRx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of SenoRx
Websites that share an audience with SenoRx (senorx.com).
Websites whose visitors overlap most with SenoRx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| bing.com | 100% | 3.5B | #10 | View details | |
search.snapdo.com | search.snapdo.com | 100% | – | – | – |
| crbard.com | 85% | – | – | View details |
Similar companies to SenoRx
10 companies that operate in the same segment as SenoRx (Women's Health & Fertility), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Internet first brand offering wearable breast pumps | 2013 | London, England, United Kingdom | USD 157.63 M | – | – | |
Silicone-filled breast and body shaping implants are designed and manufactured. | 2010 | Alajuela, Alajuela, Costa Rica | USD 121 M | USD 211.08 M | 1,020 | |
Immunotherapeutics for cancer and other diseases are developed. | 2008 | Mainz, Rhineland-palatinate, Germany | USD 805.99 M | USD 3.24 B | 6,770 | |
Developer of cell-free DNA testing for oncology, women’s health, and organ health | 2004 | Redwood City, California, United States | USD 152.1 M | USD 2.31 B | 4,430 | |
Therapeutics for women's healthcare are developed and offered. | 1997 | Princeton, New Jersey, United States | USD 124.07 M | USD 19.59 M | – | |
Provider of cell-free cancer liquid biopsy test | 2015 | San Francisco, California, United States | USD 388.62 M | – | 47 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Platform for breast ultrasound imaging | 2010 | Plymouth, Massachusetts, United States | USD 136.54 M | – | – | |
Silicone breast implants are developed for reconstruction and aesthetic surgery. | 2007 | Dublin, Ireland | USD 232.81 M | – | – | |
A minimally invasive ablation system for uterine fibroids is developed. | 2005 | Redwood City, California, United States | USD 282.54 M | – | 92 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about SenoRx
SenoRx was founded in 1998.
SenoRx is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
SenoRx(previously known as BiopSolation Medical) designs, develops, manufactures and markets minimally invasive devices for the diagnosis and treatment of breast cancer. SenoRx (NASDAQ: SENO) completed its initial public offering of common stock in March 2007. Its products include the EnCor vacuum-assisted breast biopsy system, the Contura Multi-Lumen Balloon (MLB) applicator for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer, and SenoSonix, which combines ultrasound and vacuum-assisted biopsy in one system. It offers vacuum-assisted breast biopsy systems, breast tissue markers, breast localization wires, core needle biopsy products, sentinel node detection products, and disposable bone and aspiration biopsy needles. The companys products are used with ultrasound, stereotactic, and MRI. SenoRx sells several of its products through distribution partners in more than 30 countries outside the U.S. and Canada. The companys line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx was acquired by CR Bard in 2010 for 213M.
SenoRx has 1 investor. Key investors include CR Bard.
SenoRx operates through Senorx Llc.
Yes. SenoRx was acquired by CR Bard in May 2010.